At the Metro Drug Coalition in Knoxville, they see addiction walk through the door every day. According to MDC’s Karen ...
Each year, millions of people in America are prescribed a medicine for acute pain.Now, for the first time in over 20 years, ...
Because of the recent approval by the FDA, it is anticipated payers will see an up-tick in the number of requests for this new drug. Because Journavx is not listed on the formulary, all requests ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXâ„¢ (suzetrigine), an oral, non-opioid, highly selective ...
Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing medications, has a good shot at reaching market.
The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive ...
Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...
RICHMOND, Va. (WRIC) — The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to severe acute pain in more than 20 years.
Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...
RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of Journavx were posted to FDA’s online repository ...
What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...
Ark is already conducting studies with this new class of pain medication, leveraging its strong infrastructure, experienced staff, and extensive access to patient populations. With strong community ...